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http://dx.doi.org/10.1016/j.jmii.2013Background: Human herpesvirus 6 (HHV-6) has been reported to be associated with multiple
sclerosis (MS) and GuillaineBarre´ syndrome (GBS).
Methods: We analyzed cell-free HHV-6 DNA as an indication of active infection in the periph-
eral blood and cerebrospinal fluid (CSF) of Swedish patients with GBS, patients with chronic
inflammatory demyelinating polyradiculoneuropathy, treatment-naı¨ve patients with possible
MS, interferon-b treated MS patients [with or without neutralizing antibodies (NAbs)], and con-
trol patients with headache.
Results: One of 14 GBS patients and one of eight patients with chronic inflammatory demyelin-
ating polyradiculoneuropathy were positive for HHV-6 DNA in serum. Of the 27 treatment-naı¨ve
possible MS patients, two were positive in plasma and one in CSF. HHV-6 DNA was detected in
the serum of three of 79 NAbþ patients and one of 102 NAb-interferon-b treated MS patients.
HHV-6 DNA could not be detected in the plasma or CSF of any of the 33 controls, although the
differences were not statistically significant.
Conclusion: Our results do not suggest active HHV-6 infection to be a common phenomenon in
any of the patient groups studied.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Clinical Neuroscience, The Multiple Sclerosis Research Group, CMM L8:00, SE-171 76 Stockholm,
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HHV-6 in demyelinating diseases 419Introduction
Multiple sclerosis (MS), GuillaineBarre´ syndrome (GBS), and
chronic inflammatorydemyelinating polyradiculoneuropathy
(CIDP) are diseases characterized by autoimmune demye-
lination of the nervous system. The mechanisms behind the
triggering of these diseases remain obscure, but viral in-
fections are possible candidates. Human herpesvirus 6
(HHV-6) is a ubiquitous virus1 that has been suggested to be
associated with MS2,3 and GBS4 but has not yet been investi-
gated in CIDP. Furthermore, relapse risk has been shown to
positively correlatewithHHV-6 viral load5 and anti-HHV-6 IgG
titers.6
Interferon-b (IFNb) is a first-line treatment of rela-
psingeremitting MS but also an important antiviral cyto-
kine. Treatment with IFNb has been shown to reduce the
HHV-6A DNA load in sera of patients with MS.7 Because
about 20% of patients treated with IFNb develop neutral-
izing antibodies (NAbs) against the drug, thereby blocking
the efficacy of the treatment,8 and possibly an antiviral
systemic effect, a difference regarding the level of viral
load between NAb positive and NAb negative patients might
be detected in serum from these patients.
It has been difficult to establish a causal relationship
between HHV-6 and neurological diseases. A proof of prin-
ciple would be if one could observe a clinical improvement
after antiviral treatment targeting HHV-6 in patients with
neuroinflammatory diseases, whodduring the course of
diseasedhave shown evidence of active viral infection.
However, this would require a robust method to screen for
candidate patients eligible for such a trial. Hence, we aimed
to determine the frequency of HHV-6 DNA in plasma, cere-
brospinal fluid (CSF), and serum samples of patients with
GBS, CIDP or possible MS in a clinical setting, using samples
taken as standard clinical practice. In addition, we investi-
gated whether reduced responsiveness to IFNb, due to NAbs,
leads to increased detection of HHV-6 cell free DNA.
Materials and methods
We analyzed serum and CSF samples from 14 patients with
GBS (Asbury criteria) and eight patients with CIDP (EFNS
2005 criteria). Furthermore, plasma and CSF samples from
27 treatment-naı¨ve patients who were newly diagnosed or
showed signs of MS but had not yet fulfilled the full diag-
nostic criteria for MS were analyzed.9 This group is here-
after referred to as possible MS. As controls, serum and CSF
samples from 33 headache patients investigated for
noncomplicated headache were analyzed. GBS and CIDP are
demyelinating diseases of the peripheral nervous system
(reviewed by Hughes and Cornblath10). GBS was diagnosed
by the combination of typical clinical features of ascending
paralysis and areflexia during a progressive phase lasting a
maximum of 4 weeks, in addition to features of a peripheral
demyelinating neuropathy on neurophysiological examina-
tion.11 CIDP was characterized by a subacute progressive
proximal and distal paralysis of the extremities with a
progressive phase lasting a minimum of 8 weeks
and neurophysiological features similar to those of GBS.12 In
the GBS group one patient was treated with intravenous
methyl-prednisone and one with intravenousimmunoglobulin, and in the CIDP group two patients were
treated with intravenous immunoglobulin and one with oral
prednisone and azathioprine before collection of blood and
CSF. The remainder of the patients with GBS and CIDP were
still treatment-naı¨ve at the time-point of blood and CSF
collection. MS is a demyelinating disease of the central
nervous system (reviewed by Hafler et al13) where detec-
tion of dissemination of lesions is separated in time and
space as revealed by clinical symptoms or, for example,
magnetic resonance imaging.9 We also analyzed serum
samples from patients with MS treated with IFNb, 79 pa-
tients with high titer NAbs (NAbþ) (>1280 ten-fold reduc-
tion units (TRU)/ml), and 102 patients without NAbs (NAbe)
(<10 TRU/ml) (Table 1), as determined using the myxovirus
resistance protein A (MxA) gene expression assay previously
described.14 All samples were frozen directly after collec-
tion and stored at 80C until analysis. The study was
approved by the National Ethics Committee of Sweden
(O¨-32-2005).
DNA extraction
Viral DNA was extracted from 560 mL plasma or serum and
CSF from patients with possible MS and controls with
headache. From patients with GBS and CIDP, DNA was
extracted from 200 mL serum and CSF using a commercial
kit (Qiagen, GmbH, Hilden, Germany). For contamination
control, water was added to every fifth column. DNA was
eluted in 100 mL buffer for the possible MS and headache
patients and in 80 mL for the GBS and CIDP patients and
stored at e80C.
Nested polymerase chain reaction
All samples were screened for HHV-6 DNA using a nested
polymerase chain reaction (PCR) previously described.15
Tests were considered valid if all water controls remained
negative and if the viral laboratory strains U1102 and Z29,
used as positive controls, were amplified. To discriminate
between HHV-6A and 6B, in the virus positive serum sam-
ples of NAbþ or NAb MS patients, a variant-specific nested
PCR targeting the immediate early gene was performed as
previously described.16 The MCP nested PCR sensitivity was
240 copies/mL, as determined by real-time quantitative
PCR as previously described.17 Samples from IFNb treated
patients were run in duplicates.
Statistical analysis
Fisher’s exact test (a < 0.05, two-sided) was used for sta-
tistical calculations using the software GraphPad Prism
(GraphPad Software, Inc., La Jolla, CA, USA).
Results
HHV-6 in possible MS, GBS, and CIDP plasma, serum,
or CSF samples
HHV-6 DNA was found in 3 of the 27 patients with possible
MS (2 in plasma and 1 in the CSF), as well as one of 14
Table 1 Presence of HHV-6 DNA in plasma, serum, or CSF of patients with possible MS, GBS, or CIDP, or headache controls; and










MSa 27 25 49 Plasma 7.4 (2/27) NT 0.20, 0.18,b
0.11c
CSF 3.7 (1/27) NT 0.45
GBS 14 8 65 Serum 7.1 (1/14) NT 0.30
CSF 0 (0/14)  N/A
CIDP 8 2 56 Serum 12.5 (1/8) NT 0.20
CSF 0 (0/8)  N/A
Headache 33 26 45 Plasma 0 (0/33)  
CSF 0 (0/33)  
MSd NAbþ 79 56 48 Serum 3.8 (3/79) 2*A, 1*B 0.32
MSd NAb 102 80 46 Serum 1.0 (1/102) 1*A 
a Treatment-naı¨ve patients with possible MS.
b Compared to IFNb MS patients.
c Compared to NAbe IFNb MS patients.
d IFNb treated MS patients positive (þ) or negative () for NAbs against the therapeutic IFNb.
Treatment-naı¨ve MS, GBS, and CIDP patients are compared with headache controls, if other comparisons are not specified. NAbþ MS
patients are compared with NAbe patients.
N/A Z not applicable; NT Z not tested.
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patients with possible MS were positive in both plasma and
CSF. The single HHV-6 positive patient with GBS was un-
dergoing methyl-prednisone treatment at the time-point
of blood and CSF collection. None of the 33 control pa-
tients with headache were HHV-6 positive (Table 1).
Compared to the control headache patient group, HHV-6
DNA was not detected more often in possible MS plasma
(p Z 0.20), CSF (p Z 0.45) or plasma together with CSF
(p Z 0.09), or in GBS (p Z 0.30) or CIDP (p Z 0.20) serum
samples. None of the HHV-6 positive patients with possible
MS were in clinical relapse. However, the HHV-6 positive
GBS and CIDP patients were in relapse at the point of
sampling.
HHV-6 in MS NAbD or NAbL patients
Clinical serum samples from NAbþ and NAb MS patients
(Table 1) were analyzed, and DNA was found in three of 79
NAbþ and one of 102 NAb patients, which was not sta-
tistically significant (p Z 0.32). A virus-specific nested PCR
revealed that all positive samples in the IFNb treated group
were HHV-6A, except one in the NAbþ group, which was
HHV-6B (Table 1). Furthermore, no difference was detected
in the whole group of IFNb treated patients (p Z 0.18), or
between the NAb subgroup (p Z 0.11) and treatment-
naı¨ve patients with possible MS. The NAb subgroup was
chosen for further analysis as the IFNb treatment is not
impaired by circulating NAbs. Among the HHV-6 positive
patients, one of the NAbþ patients was in relapse, whereas
the others were not.
Discussion
HHV-6 has been associated with MS2 and GBS.4 Our aim was
to replicate these findings in cross-sectional samplescollected as part of routine clinical practice. If HHV-6
infection can be consistently identified in patients’ serum
or CSF of patients with MS and GBS during active phases of
the respective diseases, treatment with antiviral therapy
targeting HHV-6 may have a positive influence on the
outcome of MS and GBS. A first step to test this hypothesis is
the capability to easily identify patients who have HHV-6
virions or anti-HHV-6 responses in serum or plasma and
CSF. Several serological methods, such as enzyme-linked
immunosorbent assay targeting antiviral IgG or IgM, or
molecular methods, such as real-time quantitative PCR,
could be used for this purpose, but nested PCR ought to be
one of the most sensitive, rapid, and cost-effective
methods and was therefore used in this study. Other re-
searchers have shown that treatment with rhIFNb reduces
the titer of HHV-6 DNA in serum,7 and thus, this effect
might not be seen in MS patients treated with rhIFNb who
have developed NAbs against the drug.
We did not find HHV-6 infection in a significantly higher
number of patients with GBS, CIDP, or MS, nor did we
observe any difference between IFNb treated and treat-
ment-naı¨ve MS patients that would allow us to confirm the
association noted in previous reports.2,4,5 Of the treatment-
naı¨ve patients with possible MS who tested positive, none
had detectable levels of HHV-6 virus in both CSF and
plasma, indicating a local infection, not passing over the
bloodebrain barrier. Screening for HHV-6 DNA in a cross-
sectional setup at one time point only might be a too
stringent approach to identify patients with active HHV-6
infection. Following patients by longitudinal sampling over
the course of the disease might be a better approach if the
aim is to detect HHV-6 as a possible agent contributing to
the pathogenesis of the disease. The limited number of
patients with active infection found of this study makes it
difficult to state that HHV-6 infection plays a major caus-
ative role in the pathogenesis of MS, GBS, and CIDP.
HHV-6 in demyelinating diseases 421Conflicts of interest
R. Gustafsson, R. Reitsma, A. Stra˚lfors, A. Lindholm, and R.
Press report no conflicts of interest. Dr. Fogdell-Hahn re-
ports receiving research grants from Biogen Idec, Sanofi-
Aventis and Merck Serono.
Acknowledgments
This study was supported by the Board of Doctoral Educa-
tion at Karolinska Institutet. We thank Malin Lundkvist and
Ingegerd Lo¨fving-Arvholm for technical assistance.
References
1. Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF,
Sturzenegger S, Kaplan M, et al. Isolation of a new virus, HBLV,
in patients with lymphoproliferative disorders. Science 1986;
234:596e601.
2. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Calabresi PA,
et al. Association of human herpes virus 6 (HHV-6) with multiple
sclerosis: increased IgM response to HHV-6 early antigen and
detection of serum HHV-6 DNA. Nat Med 1997;3:1394e7.
3. Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM.
Human herpesvirus 6 genome and antigen in acute multiple
sclerosis lesions. J Infect Dis 2003;187:1365e76.
4. Galvan M, Rotola A, Govoni V, Granieri E, Cassai E, Di Luca D.
Simultaneous GuillaineBarre syndrome and active human
herpesvirus 6 infection in the central nervous system. J Clin
Virol 2007;38:271e2.
5. Alvarez-Lafuente R, De las Heras V, Bartolome´ M, Picazo JJ,
Arroyo R. Relapsingeremitting multiple sclerosis and human
herpesvirus 6 active infection. Arch Neurol 2004;61:1523e7.
6. Simpson Jr S, Taylor B, Dwyer DE, Taylor J, Blizzard L,
Ponsonby AL, et al. Anti-HHV-6 IgG titer significantly predicts
subsequent relapse risk in multiple sclerosis. Mult Scler 2012;
18:799e806.
7. Alvarez-Lafuente R, De Las Heras V, Bartolome´ M, Picazo JJ,
Arroyo R. Beta-interferon treatment reduces humanherpesvirus-6 viral load in multiple sclerosis relapses but not in
remission. Eur Neurol 2004;52:87e91.
8. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of
interferon beta in multiple sclerosis patients with neutralizing
antibodies is titer dependent. J Neurol Neurosurg Psychiatry
2008;79:57e62.
9. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP,
Lublin FD, et al. Recommended diagnostic criteria for mul-
tiple sclerosis: guidelines from the International Panel on
the diagnosis of multiple sclerosis. Ann Neurol 2001;50:
121e7.
10. Hughes RA, Cornblath DR. GuillaineBarre syndrome. Lancet
2005;366:1653e66.
11. Asbury AK, Cornblath DR. Assessment of current diagnostic
criteria for GuillaineBarre syndrome. Ann Neurol 1990;27:
S21e4.
12. Research criteria for diagnosis of chronic inflammatory demy-
elinating polyneuropathy (CIDP). Report from an Ad Hoc Sub-
committee of the American Academy of Neurology AIDS Task
Force. Neurology 1991;41:617e8.
13. Hafler DA, Slavik JM, Anderson DE, O’Connor KC, De Jager P,
Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005;204:
208e31.
14. Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S,
Marnetto F, et al. Development and validation of a real time
PCR-based bioassay for quantification of neutralizing anti-
bodies against human interferon-beta. J Immunol Methods
2007;321:19e31.
15. Secchiero P, Carrigan DR, Asano Y, Benedetti L, Crowley RW,
Komaroff AL, et al. Detection of human herpesvirus 6 in plasma
of children with primary infection and immunosuppressed pa-
tients by polymerase chain reaction. J Infect Dis 1995;171:
273e80.
16. Yalcin S, Karpuzoglu T, Suleymanlar G, Mutlu G, Mukai T,
Yamamoto T, et al. Human herpesvirus 6 and human herpes-
virus 7 infections in renal transplant recipients and healthy
adults in Turkey. Arch Virol 1994;136:183e90.
17. Nitsche A, Mu¨ller CW, Radonic A, Landt O, Ellerbrok H, Pauli G,
et al. Human herpesvirus 6A DNA is detected frequently in
plasma but rarely in peripheral blood leukocytes of patients
after bone marrow transplantation. J Infect Dis 2001;183:
130e3.
